Monoclonal Antibodies Market - Forecasts from 2018 to 2023

August 2018 | 106 pages | ID: MBCCEA799A8EN
Knowledge Sourcing Intelligence LLP

Abstracts

The monoclonal antibodies market is projected to grow at a CAGR of 6.34% to reach US$131.766 billion by 2023, from US$91.122 billion in 2017. Monoclonal is a class of antibodies with identical offspring of a hybridoma, derived by cell division from a single ancestral cell. The market for monoclonal antibodies is driven by persistent innovation in drug development and discovery, increasing incidences of chronic diseases, favorable regulatory policies, and high adoption rate of therapeutic antibodies in emerging economies.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the monoclonal antibodies value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the monoclonal antibodies market.

Major industry players profiled as part of the report are Merck & Co. Inc., Novartis AG, Abbot, and Johnson & Johnson Services, Inc. among others.

Segmentation

The monoclonal antibodies market has been analyzed through the following segments:

• By Indication
• Inflammatory Disease
• Cancer
• Microbial Disease
• Others
• By Source
• Humanized
• Human
• Chimeric
• Murine
• By Application
• Diagnostic
• Therapeutic
• Others
• By End-User
• Hospitals & Clinics
• Research Laboratories
• By Geography
• North America
• USA
• Canada
• Mexico
• Others
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• Others
• Asia Pacific
• China
• Japan
• South Korea
• India
• Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Product Pipeline
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. MONOCLONAL ANTIBODIES MARKET BY INDICATION

5.1. Inflammatory Disease
5.2. Cancer
5.3. Microbial Disease
5.4. Others

6. MONOCLONAL ANTIBODIES MARKET BY SOURCE

6.1. Humanized
6.2. Human
6.3. Chimeric
6.4. Murine

7. MONOCLONAL ANTIBODIES MARKET BY APPLICATION

7.1. Diagnostic
7.2. Therapeutic
7.3. Others

8. MONOCLONAL ANTIBODIES MARKET BY END-USER

8.1. Hospitals & Clinics
8.2. Research Laboratories

9. MONOCLONAL ANTIBODIES MARKET BY GEOGRAPHY

9.1. North America
  9.1.1. USA
  9.1.2. Canada
  9.1.3. Mexico
  9.1.4. Others
9.2. South America
  9.2.1. Brazil
  9.2.2. Argentia
  9.2.3. Others
9.3. Europe
  9.3.1. Germany
  9.3.2. France
  9.3.3. United Kingdom
  9.3.4. Others
9.4. Middle East and Africa
  9.4.1. Saudi Arabia
  9.4.2. Israel
  9.4.3. Others
9.5. Asia Pacific
  9.5.1. China
  9.5.2. Japan
  9.5.3. South Korea
  9.5.4. India
  9.5.5. Others

10. COMPETITIVE INTELLIGENCE

10.1. Market Share of Key Players
10.2. Recent Investment and Deals
10.3. Strategies of Key Players

11. COMPANY PROFILES

11.1. Eli Lilly and Company
  11.1.1. Company Overview
  11.1.2. Financials
  11.1.3. Products and Services
  11.1.4. Recent Developments
11.2. AbbVie, Inc.
  11.2.1. Company Overview
  11.2.2. Financials
  11.2.3. Products and Services
  11.2.4. Recent Developments
11.3. Novartis AG
  11.3.1. Company Overview
  11.3.2. Financials
  11.3.3. Products and Services
  11.3.4. Recent Developments
11.4. Bristol Myers Squibb
  11.4.1. Company Overview
  11.4.2. Financials
  11.4.3. Products and Services
  11.4.4. Recent Developments
11.5. F. Hoffmann-La Roche Ltd
  11.5.1. Company Overview
  11.5.2. Financials
  11.5.3. Products and Services
  11.5.4. Recent Developments
11.6. Johnson & Johnson Services, Inc.
  11.6.1. Company Overview
  11.6.2. Financials
  11.6.3. Products and Services
  11.6.4. Recent Developments
11.7. Amgen Inc.
  11.7.1. Company Overview
  11.7.2. Financials
  11.7.3. Products and Services
  11.7.4. Recent Developments
11.8. Merck & Co. Inc.
  11.8.1. Company Overview
  11.8.2. Financials
  11.8.3. Products and Services
  11.8.4. Recent Developments
11.9. Abbot
  11.9.1. Company Overview
  11.9.2. Financials
  11.9.3. Products and Services
  11.9.4. Recent Developments
11.10. AstraZeneca PLC
  11.10.1. Company Overview
  11.10.2. Financials
  11.10.3. Products and Services
  11.10.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES